HIV Infections, Sarcoma, Kaposi
Conditions
Keywords
Skin Neoplasms, Sarcoma, Kaposi, Antineoplastic Agents
Brief summary
The purpose of this study is to see if it is safe and effective to give SU5416 to HIV-infected patients with AIDS-related Kaposi's sarcoma (KS). SU5416 may prevent the growth of KS tumors.
Detailed description
Groups of 3-6 patients are sequentially assigned to receive escalating doses of SU5416 in 33% increments. Study drug is administered as a twice-weekly intravenous injection for 4 weeks. In the absence of unacceptable toxicity, responding patients may continue on SU5416 in 4-week treatment cycles for a maximum of 1 year or until the presence of unacceptable toxicity or tumor progression.
Interventions
DRUGSU5416
Sponsors
SUGEN
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
You may be eligible for this study if you: * Are at least 18 years old. * Are HIV-positive. * Have KS with at least 5 skin lesions. * Have been in stable condition for at least 6 weeks prior to study entry, if receiving antiretroviral therapy. * Agree to use effective methods of birth control during the study.
Exclusion criteria
You will not be eligible for this study if you: * Have had surgery within 4 weeks of study entry. * Have taken certain medications, including therapy for KS, within 3 weeks prior to study entry. * Have pulmonary KS (KS in your lungs). * Have certain serious medical conditions, including liver or kidney problems, certain infections, and certain cancers. * Are allergic to Cremophor. * Have not recovered from previous cancer treatment (chemotherapy, radiotherapy, or immunotherapy). * Are pregnant.
Countries
United States
Outcome results
None listed